Zaltoprofen-13C,d3

Zaltoprofen-13C,d3

• UNSPSC Description: Zaltoprofen-13C,d3 is the 13C- and deuterium labeled Zaltoprofen. Zaltoprofen (CN100), a non-steroidal anti-inflammatory drug (NSAID), is a preferential and orally active COX-2 inhibitor, with IC50s of 1.3 and 0.34 μM for COX-1 and COX-2, respectively. Zaltoprofen exhibits powerful anti-inflammatory effects as well as an analgesic action on inflammatory pain[1][2][3].
• Target Antigen: COX; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Immunology/Inflammation;Others
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Solubility: 10 mM in DMSO
• Smiles: OC(C(C1=CC=C(SC2=C3C=CC=C2)C(CC3=O)=C1)[13C]([2H])([2H])[2H])=O
• Molecular Weight: 302.37
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Hirate K, et, al. Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors. Neurosci Res. 2006 Apr;54(4):288-94.|[3]Kameyama T, et, al. Analgesic and antiinflammatory effects of 2-(10,11-dihydro-10-oxo-dibenzo[b,f]thiepin-2-yl)propionic acid in rat and mouse. Arzneimittelforschung. 1987 Jan;37(1):19-26.|[4]Kawai S, et, al. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol. 1998 Apr 17;347(1):87-94.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported